Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients

详细信息    查看全文

• 作者：Marie Blonski (1)
  Johan Pallud (2) (3)
  Catherine Gozé (4) (5)
  Emmanuel Mandonnet (6)
  Valérie Rigau (7)
  Luc Bauchet (5) (8)
  Michel Fabbro (9)
  Patrick Beauchesne (1)
  Marie-Hélène Baron (10)
  Denys Fontaine (11)
  Philippe Peruzzi (12)
  Amélie Darlix (1)
  Hugues Duffau (5) (8)
  Luc Taillandier (1)
  
• 关键词：Low grade gliomas ; Chemotherapy ; Surgery ; Molecular biology ; Growth kinetics
• 刊名：Journal of Neuro-Oncology
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：113
• 期：2
• 页码：267-275
• 全文大小：357KB
• 参考文献：1. Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100:2622-626 CrossRef
  2. Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, Taillandier L, Capelle L (2006) Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 60:380-83 CrossRef
  3. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227-35 CrossRef
  4. Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784-791 CrossRef
  5. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338-345 CrossRef
  6. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO* task force. Eur J Neurol 17:1124-133 CrossRef
  7. Duffau H, Taillandier L, Capelle L (2006) Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma. J Neurooncol 80:171-76 CrossRef
  8. Spena G, Garbossa D, Barletta L, Prevost C, Versari P (2010) Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report. Neurol Med Chir (Tokyo) 50:410-13 CrossRef
  9. Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, Campello C, Goze C, Rigau V, Moritz-Gasser S, Kerr C, Ruda R, Soffietti R, Bauchet L, Duffau H (2012) Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol 106(2):353-66 CrossRef
  10. Mandonnet E, Jbabdi S, Taillandier L, Galanaud D, Benali H, Capelle L, Duffau H (2007) Preoperative estimation of residual volume for WHO grade II glioma resected with intraoperative functional mapping. Neuro Oncol 9:63-9 CrossRef
  11. Ius T, Angelini E, de Schotten MT, Mandonnet E, Duffau H (2011) Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: towards a “minimal common brain- Neuroimage 56:992-000 CrossRef
  12. Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61:484-90 CrossRef
  13. Pallud J, Varlet P, Devaux B, Geha S, Badoual M, Deroulers C, Page P, Dezamis E, Daumas-Duport C, Roux FX (2011) Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology 74:1724-731 CrossRef
  14. Mandonnet E, Pallud J, Clatz O, Taillandier L, Konukoglu E, Duffau H, Capelle L (2008) Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev 31:263-69 CrossRef
  15. Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, Cornu P, Van Effenterre R, Alvord EC Jr, Capelle L (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524-28 CrossRef
  16. Pallud J, Mandonnet E, Deroulers C, Fontaine D, Badoual M, Capelle L, Guillet-May F, Page P, Peruzzi P, Jouanneau E, Frenay M, Cartalat-Carel S, Duffau H, Taillandier L (2010) Pregnancy increases the growth rates of World Health Organization grade II gliomas. Ann Neurol 67:398-04
  17. Berger MS (1995) Functional mapping-guided resection of low-grade gliomas. Clin Neurosurg 42:437-52
  18. Pallud J, Capelle L, Taillandier L, Fontaine D, Mandonnet E, Guillevin R, Bauchet L, Peruzzi P, Laigle-Donadey F, Kujas M, Guyotat J, Baron MH, Mokhtari K, Duffau H (2009) Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol 11:176-82 CrossRef
  19. Duffau H (2005) Intraoperative cortico-subcortical stimulations in surgery of low-grade gliomas. Expert Rev Neurother 5:473-85 CrossRef
  20. Duffau H (2007) Contribution of cortical and subcortical electrostimulation in brain glioma surgery: methodological and functional considerations. Neurophysiol Clin 37:373-82 CrossRef
  21. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-09 CrossRef
  22. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954-958
  23. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-02 CrossRef
  24. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996-998 CrossRef
  25. Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J, Mokhtari K, Guyotat J, Jouanneau E, Sunyach MP, Frappaz D, Honnorat J, Ducray F (2010) Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 12(10):1078-082 CrossRef
  26. Pallud J, Llitjos JF, Dhermain F, Varlet P, Dezamis E, Devaux B, Souillard-Scemama R, Sanai N, Koziak M, Page P, Schlienger M, Daumas-Duport C, Meder JF, Oppenheim C, Roux FX (2012) Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 14:496-05 CrossRef
  27. Mandonnet E, Capelle L, Duffau H (2006) Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns. J Neurooncol 78:179-85 CrossRef
  28. Pallud J, Devaux B, Daumas-Duport C, Oppenheim C, Roux FX (2005) Glioma dissemination along the corticospinal tract. J Neurooncol 73:239-40 CrossRef
  29. Duffau H (2009) Does post-lesional subcortical plasticity exist in the human brain? Neurosci Res 65:131-35 CrossRef
  30. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831-836 CrossRef
  31. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY (2011) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560-566 CrossRef
  32. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-154 CrossRef
  33. Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-43 CrossRef
  34. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-861 CrossRef
  35. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792-795 CrossRef
  36. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17:4588-599 CrossRef
  37. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330-37 CrossRef
  38. Goze C, Rigau V, Gibert L, Maudelonde T, Duffau H (2009) Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol 91:1- CrossRef
  39. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-084 CrossRef
  40. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, Mokhtari K, Polivka M, Bernier M, Chretien F, Couvelard A, Capelle L, Duffau H, Cornu P, Broet P, Thillet J, Carpentier AF, Sanson M, Hoang-Xuan K, Delattre JY (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58:322-26 CrossRef
  41. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-479 CrossRef
  
• 作者单位：Marie Blonski (1)
  Johan Pallud (2) (3)
  Catherine Gozé (4) (5)
  Emmanuel Mandonnet (6)
  Valérie Rigau (7)
  Luc Bauchet (5) (8)
  Michel Fabbro (9)
  Patrick Beauchesne (1)
  Marie-Hélène Baron (10)
  Denys Fontaine (11)
  Philippe Peruzzi (12)
  Amélie Darlix (1)
  Hugues Duffau (5) (8)
  Luc Taillandier (1)
  
  1. Neuro-Oncology Unit, Nancy University Hospital, 29, Avenue du Maréchal Lattre de Tassigny, 54035, Nancy, France
  2. Department of Neurosurgery, Sainte-Anne Hospital, 1, rue Cabanis, 75674, Paris, France
  3. University Paris Descartes, Paris, France
  4. Hormone and Cell Biology Laboratory, Arnaud de Villeneuve University Hospital, 37, Avenue du Doyen Gaston Giraud, 34295, Montpellier, France
  5. National Institute for Health and Medical Research (INSERM)—U1051 Laboratory, Institute for Neurosciences of Montpellier, University Hospital, Montpellier, France
  6. Department of Neurosurgery, Lariboisière Hospital, 2, rue Ambroise Paré, 75010, Paris, France
  7. Cytology and Anatomical Pathology Laboratory, Gui de Chauliac University Hospital, 80, rue Augustin Fliche, 34295, Montpellier, France
  8. Department of Neurosurgery, Gui de Chauliac University Hospital, 80, rue Augustin Fliche, 34295, Montpellier, France
  9. Department of Oncology, Val D’Aurelle Center of Cancer Treatment, 208, rue des Apothicaires, 34298, Montpellier, France
  10. Department of Radiotherapy, Jean Perrin Center of Cancer Treatment, 58, rue Montalembert, 63011, Clermont-Ferrand, France
  11. Department of Neurosurgery, Pasteur University Hospital, 30, Avenue de la Voie Romaine, 06000, Nice, France
  12. Department of Neurosurgery, Maison Blanche University Hospital, 55, rue Cognacq Jay, 51092, Reims, France
  
• ISSN：1573-7373

文摘

The involvement of eloquent brain areas may preclude the total/subtotal surgical resection of diffuse low-grade gliomas (DLGGs). The feasibility and functional tolerance of neoadjuvant chemotherapy have been demonstrated in such cases. The present study assesses the clinical and radiological impact of neoadjuvant chemotherapy on the natural course of DLGG. Seventeen patients without feasible surgical resection (infiltration of functional areas and/or large contralateral extension) were retrospectively selected. Temozolomide based neoadjuvant chemotherapy was initiated, inducing a tumor volume decrease and allowing a functional based maximal surgical resection. The median follow-up since initial radiological diagnosis was 5.9?years (range, 1.4-1). The median time to malignant transformation was 5.9?years. Six patients (35?%) had 1p19q codeletion, 12 patients (70?%) with IDH mutation and MGMT promoter methylation, and eight patients (47?%) had p53 overexpression. Chemotherapy reduced tumor volume (median ?5.6?%, range ?1.6 to ?.1?%) in contralateral hemisphere through the corpus callosum in seven cases (41?%) and in ipsi-lesional functional areas in ten cases (59?%). Chemotherapy significantly decreased the imaging tumor growth (measured by the velocity of diametric expansion VDE) with a median of ?.2?mm/year (range, ?9.8 to ?.9?mm/year) (p?<?0.001). A tumor volume decrease of more than 20?% was correlated with a lower postoperative residual tumor (median 2?cc, p?=?0.04), a greater extent of resection (93.1 vs. 89.5?%), a higher probability of total/subtotal removal. Neoadjuvant chemotherapy with Temozolomide could optimize the surgical resection of DLGGs and could impact their natural history. Further large prospective studies with long-term follow-up are needed.